OncologyTube brings you an exclusive look at the AMPLIFY-201 Phase 1 trial. Furthermore, this study highlights ELI-002 2P, a lymph…
Browsing: Overall Survival
At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell…
What’s New at ASCO 2025? The ASCO 2025 conference in Chicago brought exciting news for cancer care. A major study,…
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD,…
The GALAXY Study has provided compelling data that highlights the predictive value of circulating tumor DNA (ctDNA) status in colorectal…